within Pharmacolibrary.Drugs.ATC.J;

model J07BN02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J07BN02</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>COVID-19 vaccines of the viral vector, non-replicating type (e.g., ChAdOx1 nCoV-19/AstraZeneca and Ad26.COV2.S/Johnson & Johnson) use non-replicating adenovirus vectors to deliver genetic material encoding SARS-CoV-2 spike protein. These vaccines are used for prevention of COVID-19 and are authorized for emergency or standard use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>No formal pharmacokinetic (PK) studies are conducted for non-replicating viral vector COVID-19 vaccines in humans, as traditional PK parameters do not apply to vaccines. Estimated values based on typical administration to healthy adults.</p><h4>References</h4><ol><li><p>Marquez-Martinez, S, et al., &amp; Khan, S (2024). Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses. <i>PloS one</i> 19(4) e0299215–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0299215&quot;>10.1371/journal.pone.0299215</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38626093/&quot;>https://pubmed.ncbi.nlm.nih.gov/38626093</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J07BN02;
